Development of QSAR Models to Identify Mycobacterium tuberculosis enoyl-ACP-reductase Enzyme Inhibitors

Tuberculosis is a matter of global concern due to its prevalence in developing countries and the ability of mycobacterium to present resistance to existing therapeutic regimens. In this context, the present project proposes the QSAR (Quantitative Structure-Activity Relationships) modeling, as a way of identifying and evaluating, in silico, the estimated inhibitory activity of candidate molecules for the molecular improvement stages and/or in vitro assays, reducing research time and financial costs. For this purpose, the SAR (Structure-Activity Relationships) study conducted by He, Alian and Montellano (2007) was used on a series of arylamides, tested as inhibitors of the enzyme enoyl-ACP-reductase (InhA) of Mycobacterium tuberculosis . The Hansh-Fujita (classical) and CoMFA (Comparative Molecular Field Analysis) QSAR models were developed. The classic QSAR model obtained the best statistical result, using Multiple Linear Regression (MLR), with internal validation with correlation factor R 2 = 0.9012 and predictive quality, according to the Stone-Geisser indicator Q 2 = 0.8612. In the external validation, a correlation factor R 2 = 0.9298 and a Q 2 = 0.720 was obtained, indicating a highly predictive mathematical model. The CoMFA Model managed to obtain a Q 2 = 0.6520 in the internal validation, which allowed the energy fields around the molecules used to be estimated, this is essential information to foster molecular improvement. A library of small molecules was built, with analogs to those used in the SAR study, which were subjected to classic QSAR function, resulting in a group of ten molecules with high estimated biological activity. The molecular docking results suggest that the ten analogs identified by the classical QSAR model presented favorable estimated free energy of binding. The conclusion points to the QSAR methodology as an efficient and effective tool in the search and identification of promising drug-like molecules.

[1]  R. Verma,et al.  Design, synthesis, evaluation, and molecular dynamic simulation of triclosan mimic diphenyl ether derivatives as antitubercular and antibacterial agents , 2020, Structural Chemistry.

[2]  Rino Ragno,et al.  www.3d-qsar.com: a web portal that brings 3-D QSAR to all electronic devices—the Py-CoMFA web application as tool to build models from pre-aligned datasets , 2019, Journal of Computer-Aided Molecular Design.

[3]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[4]  Keun Woo Lee,et al.  Biochemical and Structural Basis of Triclosan Resistance in a Novel Enoyl-Acyl Carrier Protein Reductase , 2018, Antimicrobial Agents and Chemotherapy.

[5]  L. Maveyraud,et al.  An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors. , 2018, European journal of medicinal chemistry.

[6]  M. P. Matsoso,et al.  Tuberculosis and antimicrobial resistance – new models of research and development needed , 2017, Bulletin of the World Health Organization.

[7]  G. N. Sastry,et al.  CoMFA, CoMSIA, kNN MFA and docking studies of 1,2,4-oxadiazole derivatives as potent caspase-3 activators , 2017 .

[8]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[9]  C. Vilchèze,et al.  Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities , 2014, Microbiology spectrum.

[10]  Gaurao V. Dhoke,et al.  3D-QSAR and molecular docking studies of amino-pyrimidine derivatives as PknB inhibitors , 2014 .

[11]  Belen Pedrique,et al.  The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. , 2013, The Lancet. Global health.

[12]  A. Tropsha,et al.  Does Rational Selection of Training and Test Sets Improve the Outcome of QSAR Modeling? , 2012, J. Chem. Inf. Model..

[13]  José M. García,et al.  High-Throughput parallel blind Virtual Screening using BINDSURF , 2012, BMC Bioinformatics.

[14]  Joel S. Freundlich,et al.  Triclosan Derivatives: Towards Potent Inhibitors of Drug‐Sensitive and Drug‐Resistant Mycobacterium tuberculosis , 2009, ChemMedChem.

[15]  P. Ortiz de Montellano,et al.  Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. , 2007, Bioorganic & medicinal chemistry.

[16]  Kunal Roy,et al.  On Selection of Training and Test Sets for the Development of Predictive QSAR models , 2006 .

[17]  Igor V. Tetko,et al.  Virtual Computational Chemistry Laboratory – Design and Description , 2005, J. Comput. Aided Mol. Des..

[18]  J. T. Crawford,et al.  ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates , 2003, Antimicrobial Agents and Chemotherapy.

[19]  H. Berman,et al.  Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank , 2022 .

[20]  Carlos A. Montanari,et al.  Seleção de variáveis em QSAR , 2002 .

[21]  H. Kubinyi.  Comparative Molecular Field Analysis (CoMFA) , 2002 .

[22]  Anderson Coser Gaudio,et al.  BuildQSAR: A New Computer Program for QSAR Analysis , 2000 .

[23]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[24]  V. Barnett,et al.  Applied Linear Statistical Models , 1975 .

[25]  Arthur J Olson,et al.  Small-molecule library screening by docking with PyRx. , 2015, Methods in molecular biology.

[26]  Wynne W. Chin.  How to Write Up and Report PLS Analyses , 2010 .

[27]  Roberto Todeschini,et al.  Handbook of Molecular Descriptors , 2002 .